Failure of Medical Therapy in Pulmonary Arterial Hypertension Is There an Alternative Diagnosis?

被引:21
|
作者
Harch, Susan [1 ]
Whitford, Helen [2 ]
McLean, Catriona [1 ]
机构
[1] Alfred Hosp, Dept Anat Pathol, Melbourne, Vic 3181, Australia
[2] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3181, Australia
关键词
VENOOCCLUSIVE DISEASE; PROSTACYCLIN; BOSENTAN; EDEMA;
D O I
10.1378/chest.08-2006
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Despite the development of targeted therapies for pulmonary arterial hypertension (PAH), some patients fail to respond to medical therapy. There are a number of types of PAH, one of which is pulmonary venoocclusive disease (PVOD). Unlike other PAH types, the hallmark pathology of PVOD is fibrous occlusion of the small venules, potentially with arterial involvement. It was hypothesized that a lack of response to medical therapy in clinically diagnosed PAH can be explained by misdiagnosed PVOD. Methods: This study reviewed cases of 14 patients with clinically diagnosed PAH who had failed to respond to medical therapy and had lung tissue available from autopsy or explant. Control samples (n = 6) were obtained from lungs explanted for other causes, and at previous transthoracic echocardiogram excluded pulmonary hypertension. Comprehensive vessel morphometry was performed, and the clinical data reviewed. Results: Vessel analysis confirmed 86% of case patients had PVOD and 14% had arterial-only PAH (artPAH). In the PVOD case patients, significant pathology was present in all vessel types with similar obstructive, intimal fibrosis in the venules (p < 0.0001) and arterioles (p < 0.0001). This was considerably different from the intimal concentric laminar smooth muscle proliferation in the artPAH cases. There were no significant differences in clinical presentation between PVOD and artPAH case patients. Pulmonary edema was not observed in the PVOD cases. Conclusions: PVOD is an underdiagnosed and commonly, misdiagnosed cause of pulmonary hypertension, which may present with a failure to respond to medical therapy. Further studies on PVOD may help confirm whether a change in its classification as a type of PAH is necessary. (CHEST 2009; 135:1462-1469)
引用
收藏
页码:1462 / 1469
页数:8
相关论文
共 50 条
  • [41] Epoprostenol Therapy for Pulmonary Arterial Hypertension
    Akagi, Satoshi
    Nakamura, Kazufumi
    Matsubara, Hiromi
    Ogawa, Aiko
    Sarashina, Toshihiro
    Ejiri, Kentaro
    Ito, Hiroshi
    ACTA MEDICA OKAYAMA, 2015, 69 (03) : 129 - 136
  • [42] Bosentan therapy for pulmonary arterial hypertension
    Provencher, Steeve
    Jais, Xavier
    Sitbon, Olivier
    FUTURE CARDIOLOGY, 2005, 1 (03) : 299 - 309
  • [43] Prostacyclin Therapy for Pulmonary Arterial Hypertension
    Ruan, Cheng-Huai
    Dixon, Richard A. F.
    Willerson, James T.
    Ruan, Ke-He
    TEXAS HEART INSTITUTE JOURNAL, 2010, 37 (04) : 391 - 399
  • [44] Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension
    Bartenstein, Philipp
    Saxer, Stephanie
    Appenzeller, Paula
    Schwarz, Esther
    Lichtblau, Mona
    Ulrich, Silvia
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [45] Supportive Therapy in pulmonary arterial Hypertension
    Gruenig, E.
    Ehlken, N.
    Hohenforst-Schmidt, W.
    Krueger, U.
    Krueger, S.
    Lichtblau, M.
    Marra, A. M.
    Meyer, A.
    Olschewski, H.
    Olsson, K. M.
    Staehler, G.
    Sablotzki, A.
    Skowasch, D.
    Wenter, C.
    Kaehler, C.
    Ulrich, S.
    Speich, R.
    Lang, I.
    Hoenen, S.
    Meyer, F. J.
    Bonderman, D.
    Stark, W.
    Hoeper, M. M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S136 - S141
  • [46] Beraprost therapy for pulmonary arterial hypertension
    Barst, RJ
    McGoon, M
    McLaughlin, V
    Tapson, V
    Oudiz, R
    Shapiro, S
    Robbins, IM
    Channick, R
    Badesch, D
    Rayburn, BK
    Flinchbaugh, R
    Sigman, J
    Arneson, C
    Jeffs, R
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) : 2119 - 2125
  • [47] Combination Therapy in Pulmonary Arterial Hypertension
    Pugh, Meredith E.
    Hemnes, Anna R.
    Robbins, Ivan M.
    CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 841 - +
  • [48] Ambrisentan therapy for pulmonary arterial hypertension
    Galié, N
    Badesch, D
    Oudiz, R
    Simonneau, G
    McGoon, MD
    Keogh, AM
    Frost, AE
    Zwicke, D
    Naeije, R
    Shapiro, S
    Olschewski, H
    Rubin, LJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (03) : 529 - 535
  • [49] Tadalafil Therapy for Pulmonary Arterial Hypertension
    Galie, Nazzareno
    Brundage, Bruce H.
    Ghofrani, Hossein A.
    Oudiz, Ronald J.
    Simonneau, Gerald
    Safdar, Zeenat
    Shapiro, Shelley
    White, R. James
    Chan, Melanie
    Beardsworth, Anthony
    Frumkin, Lyn
    Barst, Robyn J.
    CIRCULATION, 2009, 119 (22) : 2894 - U65
  • [50] Combination Therapy in Pulmonary Arterial Hypertension
    Channick, Richard N.
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (08): : 16C - 20C